Skip to content

EV / sales at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
Stryker logo
StrykerSYK
5.4×-1.3×
CONMED logo
CONMEDCNMD
1.4×-0.7×
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
2.9×-0.7×
Enovis logo
EnovisENOV
1.2×-0.5×
OrthoPediatrics logo
OrthoPediatricsKIDS
1.6×-1.0×

Other financials

Income statement

See full
Revenue$47.2M-10.2%
Gross profit$37.4M-10.7%
Operating income-$17.2M-10.2%
Net income-$18.0M-12.8%
EPS (diluted)-$0.28-12.0%

Balance sheet

See full
Cash & equivalents$9.5M-28.6%
Total debt$71.6M+3.2%
Total equity$77.2M-26.7%
Total assets$184.1M-10.6%

Cash flow

See full
Operating cash flow$7.2M+72.5%
CapEx$3.1M-13.6%
Free cash flow$4.2M+538%

Valuation

See full
Market cap$258.19M-26.6%
Enterprise value$320.25M-22.6%
P/S1.3×-0.4×

Profitability

See full
Gross margin79.7%-0.5pp
Operating margin-26.9%+2.5pp
Net margin-29.4%+6.1pp
FCF margin-12.5%-2.8pp

Returns & leverage

See full
Return on equity-66.9%+57.5pp
Debt / equity0.9×+0.3×
Current ratio3.6×-0.9×

Where this comes from

Calculated from Treace Medical Concepts, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Treace Medical Concepts, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Treace Medical Concepts, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Treace Medical Concepts, Inc.'s EV / sales?
Treace Medical Concepts, Inc. (TMCI) reported EV / sales of 0.7× in Q1 2026.
How has Treace Medical Concepts, Inc.'s EV / sales changed year-over-year?
Treace Medical Concepts, Inc.'s EV / sales decreased by 74.0% year-over-year, from 2.8× to 0.7×.
What is the long-term trend for Treace Medical Concepts, Inc.'s EV / sales?
Over 4 years (2021 to 2025), Treace Medical Concepts, Inc.'s EV / sales has grown at a -43.5% compound annual growth rate (CAGR), from 10× to 1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.